1. Summary
Canine lymphoma is a common and aggressive cancer affecting dogs, comprising a diverse group of hematologic malignancies that arise from lymphoid tissues. Recent advances in diagnostics, treatment options, and ongoing research aim to improve the prognosis and quality of life for affected dogs. This page provides an overview of canine lymphoma, including its classification, diagnostic approaches, treatment strategies, and future research opportunities. In particular, biospecimens like primary cells, tumor cells, and various biological fluids (e.g., blood and urine) play a pivotal role in enhancing diagnostic accuracy and developing novel therapies.
2. Introduction
Lymphoma in dogs represents one of the most common cancers, affecting lymphoid tissues such as lymph nodes, spleen, and bone marrow. It is a highly heterogeneous disease with different biological behaviors, clinical presentations, and responses to treatment depending on the subtype. The need for more accurate diagnostic tools and effective therapies is a priority in veterinary oncology, driven by the recent advances in understanding the genetic and molecular pathways involved in the disease. The use of biospecimens, including peripheral blood mononuclear cells (PBMCs), fine-needle biopsy tissues, and cryopreserved samples, is crucial for both diagnosis and research into new treatment modalities.
3. Classification and Incidence
Canine lymphoma is classified according to cell type (B-cell vs. T-cell) and malignancy grade. The World Health Organization (WHO) classification system, which considers histologic and immunophenotypic parameters, remains the gold standard for diagnosis(VMS3-10-e1398) . Among the subtypes, B-cell lymphoma is more common and typically has a better prognosis, whereas T-cell lymphoma, particularly high-grade forms, is associated with poorer outcomes(VMS3-10-e1398) . Recent studies also emphasize the role of newer classifications like the Kiel classification, which helps predict survival outcomes based on the morphological subtype(VMS3-10-e1398).
4. Diagnosis
Accurate diagnosis of canine lymphoma requires a multimodal approach, combining cytologic evaluation of fine-needle aspirates, histopathology, and immunophenotyping . Flow cytometry and immunocytochemistry are valuable tools to determine the immunophenotype (B-cell vs. T-cell), which is critical for prognosis and treatment planning. The use of biospecimens such as blood, urine, and lymph node aspirates helps to identify biomarkers and molecular signatures associated with specific lymphoma subtypes . Additionally, molecular techniques like PCR for antigen receptor rearrangements (PARR) and miRNA profiling are emerging as diagnostic aids that provide insight into the genetic underpinnings of the disease .
5. Treatment
The treatment of canine lymphoma is primarily focused on chemotherapy, with protocols like CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) being the most common(VMS3-10-e1398). Newer approaches have integrated immunotherapies and targeted therapies, guided by molecular profiling of the tumor(VMS3-10-e1398) . Chemotherapy can induce remission in many cases, but relapse is common, particularly in T-cell lymphomas(VMS3-10-e1398). Biospecimens such as tumor cells and PBMCs are increasingly being used to test new therapeutic compounds, aiming to develop personalized medicine strategies based on the genetic profile of the tumor(fvets-11-1442964) .
6. Future Research Opportunities
Current research into canine lymphoma is focused on understanding the genetic and molecular mechanisms driving the disease. Biospecimens such as frozen tissues and tumor cells from biopsies are essential for molecular research, helping identify new drug targets and diagnostic biomarkers (fvets-11-1442964). Artificial intelligence and machine learning are also being applied to improve diagnostic accuracy and predict treatment responses . Future therapies may involve the use of personalized medicine based on molecular profiling, as well as the integration of novel drug compounds that target specific pathways involved in cancer cell growth and survival(fvets-11-1442964) .
- Our Products and Services
- Dissociated tumor cells from canine lymphoma: Ideal for in vitro studies, providing detailed insights into tumor biology and drug responses.
- Cell line establishment services from canine lymphoma: Custom cell models developed from patient-derived samples for long-term research.
- Serum from canine lymphoma: Rich in circulating biomarkers, useful for diagnostic and therapeutic research.
- Plasma from canine lymphoma: Valuable for molecular analysis and biomarker discovery.
- Swabs from canine lymphoma: Non-invasive samples for studying the tumor microenvironment.
- Urine from canine lymphoma: A source of metabolic and diagnostic markers for disease monitoring.
- Stool from canine lymphoma: Useful for gastrointestinal involvement studies or microbiome research.
These products offer high-quality samples, supporting advanced research and the development of innovative diagnostics and treatments for canine lymphoma.
How to order:
For orders or enquiries you can contact us at info@lab4paws.com or call us at +49 172 460 5978 (Europe) or +1 617 982 1785 (US).
References
- VMS3-10-e1398.pdf: Prognostic role of the updated Kiel classification in canine high-grade T-cell lymphomas(VMS3-10-e1398) .
- fvets-11-1442964.pdf: Research Topic on canine lymphoma pathogenesis, diagnosis, prognosis, and treatment .
- 9782832552261.PDF: Advances in molecular tools for canine lymphoma diagnosis and therapy(fvets-11-1442964) .
